Bleselumab + Basiliximab + Mycophenolate Mofetil (MMF) + Tacrolimus Capsules + Methylprednisone + Prednisone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Trial Timeline
May 22, 2017 → May 18, 2021
NCT ID
NCT02921789About Bleselumab + Basiliximab + Mycophenolate Mofetil (MMF) + Tacrolimus Capsules + Methylprednisone + Prednisone
Bleselumab + Basiliximab + Mycophenolate Mofetil (MMF) + Tacrolimus Capsules + Methylprednisone + Prednisone is a phase 2 stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT02921789. Target conditions include Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS).
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02921789 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Transplantation